Form 4: Lyell Immunopharma Executive Receives Stock Grant
Insider Transaction (Form 4)
Jarrad Mattieu Aguirre, Chief Medical Officer of Lyell Immunopharma, Inc., received 47,500 shares of common stock on September 10, 2026.
Summary
- Grant/award: acquired 47,500 Option (right to buy) on September 10, 2026; holds 47,500 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Jarrad Mattieu Aguirre — Officer (Chief Medical Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-10 | Grant/award | Option (right to buy) | 47,500 | — | — | 47,500 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-10 | Grant/award (47,500 shares) |
Keywords
insider transaction, Form 4, LYEL, Lyell Immunopharma, Inc., neutral, Jarrad Mattieu Aguirre
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.